Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access February 4, 2014

Quantifying pharmacodynamic interaction between atenolol and valsartan

Zuzana Rausova EMAIL logo , Jana Chrenova , Viliam Mojto and Ladislav Dedik
From the journal Open Medicine

Abstract

We used mathematical modeling in order to determine the pharmacodynamic relationship between antihypertensive drugs atenolol and valsartan, by evaluating their effects on heart rate (HR), systolic blood pressure (SP) and diastolic blood pressure (DP). A group of twelve healthy male volunteers received a single oral dose of 100 mg of atenolol and 160 mg of valsartan, both separately and in combination. Pharmacokinetic (PK), pharmacokinetic/pharmacodynamic (PK/PD) and pharmacodynamic (PD) systems were proposed and PD model of atenolol and valsartan concentration-time profiles and PK/PD model of blood pressure and heart rate effects after administration of single doses of atenolol and valsartan and their combination were constructed. Parameters of PD system, such as gain and mean effect time, were obtained by analysis of PK and PK/PD systems. Modeling of PK and PK/PD systems and their analysis to obtain the PD results could considerably change the view o treatment of individual diseases in terms of greater knowledge of pharmacokinetics and pharmacodynamics of drugs.

[1] Del Giaccio A., Eblen-Zajjur A., Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol, Invest Clin., 2010, 51, 77–86 Search in Google Scholar

[2] Volpe M., Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan, Expert Rev Cardiovasc Ther., 2012, 10, 1061–72, DOI: 10.1586/erc.12.80 http://dx.doi.org/10.1586/erc.12.8010.1586/erc.12.80Search in Google Scholar

[3] Díez J., Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension, Clin Ther., 2006, 28, 832–48 http://dx.doi.org/10.1016/j.clinthera.2006.06.00210.1016/j.clinthera.2006.06.002Search in Google Scholar

[4] Antalóczy Z., Kékes E., Anti-anginal effect of Tenormin (atenolol), Ther Hung, 1992, 40, 58–63 Search in Google Scholar

[5] Bhatia V., Bhatia R., Mathew B., Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies, Cardiol Rev., 2005, 13, 297–303 http://dx.doi.org/10.1097/01.crd.0000148236.34855.1810.1097/01.crd.0000148236.34855.18Search in Google Scholar

[6] Jugdutt B.I., Valsartan in the treatment of heart attack survivors, Vasc Health Risk Manag., 2006, 2, 125–38 http://dx.doi.org/10.2147/vhrm.2006.2.2.12510.2147/vhrm.2006.2.2.125Search in Google Scholar

[7] Carré A., (1998). Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients, Drugs, 1998, 56 Suppl 2, 23–30 http://dx.doi.org/10.2165/00003495-199856002-0000310.2165/00003495-199856002-00003Search in Google Scholar

[8] Morgan J.M., Palmisano M., Piraino A., Hirschhorn W., Spencer S., Prasad P.P., Ortiz M., Lloyd P., The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther., 1997, 61, 35–44 http://dx.doi.org/10.1016/S0009-9236(97)90180-610.1016/S0009-9236(97)90180-6Search in Google Scholar

[9] Hill A.V., The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves, J Physiol, 1910, 40, iv–vii Search in Google Scholar

[10] Mager D.E., Wyska E., Jusko W.J., Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos., 2003, 31, 510–8 http://dx.doi.org/10.1124/dmd.31.5.51010.1124/dmd.31.5.510Search in Google Scholar PubMed

[11] L. Dedík, M. Ďurišová, Advanced system approach based methods for modeling biomedical systems, in: International Conference of Computational Methods in Sciences and Engineering (ICCMSE 2004), eds. T. Simos and G. Maroulis, pp. 136–139 (Koninklijke Brill NV, Leiden, Netherlands, 2004) 10.1201/9780429081385-34Search in Google Scholar

[12] M. Ďurišová, L. Dedík, New mathematical methods in pharmacokinetic modeling, Basic Clin. Pharmacol. Toxicol. 96 (2005) 335–342 http://dx.doi.org/10.1111/j.1742-7843.2005.pto_01.x10.1111/j.1742-7843.2005.pto_01.xSearch in Google Scholar PubMed

[13] Czendlik CH., Sioufi A., Preiswerk G., Howald H., Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol, 1997, 52, 451–459 http://dx.doi.org/10.1007/s00228005031810.1007/s002280050318Search in Google Scholar PubMed

[14] Rosenbaum D.A., Is dynamical systems modeling just curve fitting?. Motor Control,1998, 2, 101–104 10.1123/mcj.2.2.101Search in Google Scholar

[15] Dedík L., Ďurišová M., System approach in technical, environmental, and bio-medical studies, 1999, Slovak University of Technology, Bratislava Search in Google Scholar

[16] Akaike H., Canonical correlation analysis of time series and the use of an information criterion. In: Mehra R.K., Lainiotis D.G. (Eds.), System Identification: Advances and Case Studies. (pp 27–96). Academic Press, New York, 1976 http://dx.doi.org/10.1016/S0076-5392(08)60869-310.1016/S0076-5392(08)60869-3Search in Google Scholar

[17] Najib N.M., Idkaidek N., Adel A., Mohammed B., Al-Masri S., Admour I., Alam S.M., Dham R., Qumaruzaman., Comparative bioavailability of two brands of atenolol 100 mg tablets (Tensotin and Tenormin) in healthy human volunteers. Biopharm Drug Dispos., 2005, 26, 1–5 http://dx.doi.org/10.1002/bdd.41610.1002/bdd.416Search in Google Scholar

[18] Spahn H., Kirch W., Mutschler E., Ohnhaus E.E., Kitteringham N.R., Lögering H.J., Paar D., Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br J Clin Pharmacol., 1984, 17Suppl 1,97S–102S http://dx.doi.org/10.1111/j.1365-2125.1984.tb02439.x10.1111/j.1365-2125.1984.tb02439.xSearch in Google Scholar

[19] Wu F.L., Chen P.F., Lee Y.J., Chen R.R.L., Comparative Pharmacokinetics of Two Atenolol Products. J Food Drug Anal, 2003, 11, 4–7 10.38212/2224-6614.2724Search in Google Scholar

[20] Spínola A.C., Almeida S., Filipe A., Neves R., Trabelsi F., Farré A., Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther., 2009, 31, 1992–2001. DOI: 10.1016/j.clinthera.2009.09.002. http://dx.doi.org/10.1016/j.clinthera.2009.09.00210.1016/j.clinthera.2009.09.002Search in Google Scholar

[21] Zakeri-Milani P., Valizadeh H., Islambulchilar Z., Nemati M., Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. Arzneimittelforschung, 2010, 60,76-80. DOI: 10.1055/s-0031-1296252. 10.1055/s-0031-1296252Search in Google Scholar

[22] Sioufi A., Marfil F., Jaouen A., Cardot J.M., Godbillon J., Ezzet F., Lloyd P., The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos., 1998, 19, 237–44 http://dx.doi.org/10.1002/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-710.1002/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-7Search in Google Scholar

Published Online: 2014-2-4
Published in Print: 2014-2-1

© 2013 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 30.11.2022 from frontend.live.degruyter.dgbricks.com/document/doi/10.2478/s11536-013-0252-8/html
Scroll Up Arrow